Scleritis following intravitreal brolucizumab injection: a case series.
Brolucizumab
Case report
Intraocular inflammation
Scleritis
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
28
08
2023
accepted:
22
01
2024
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
28
2
2024
Statut:
epublish
Résumé
This study reports the first cases of scleritis following intravitreal brolucizumab (IVBr) injection for nAMD, emphasizing the need to be aware of the possibility of scleritis following IVBr injections. Case 1. A 74-year-old Japanese man with nAMD complained of conjunctivitis and decreased vision in the right eye 8 days after his eighth IVBr injection. Examination revealed scleritis without anterior inflammation. Topical 0.1% betamethasone and 0.3% gatifloxacin eye drops were started. The scleritis worsened in the following 2 weeks and became painful. He underwent sub-Tenon's capsule triamcinolone acetonide (STTA) injection. Two days later, he returned with a complaint of severe vision loss. Fundus examination revealed retinal artery occlusion, vasculitis, and vitreous opacity in the right eye. Vitreous surgery was performed. An 85-year-old Japanese woman with nAMD in the right eye complained of reddening of the eye 27 days after her fifth IVBr injection. Examination showed conjunctivitis and scleritis without anterior inflammation in the right eye. She was started on 0.1% fluorometholone and 0.5% levofloxacin hydrate eye drops. The scleritis worsened in the following 3 weeks. Her treatment was switched to 0.1% betamethasone eye drops. One month later, the scleritis had improved and a sixth IVBr injection was administered. There was no worsening of the scleritis at that time. However, 1 month after a seventh IVBr injection, she complained of severe hyperemia and decreased vision. Fundus examination revealed vitreous opacification. She underwent STTA, and the vitreous opacity improved in 24 days. Case 3. A 57-year-old Japanese man with nAMD complained of pain and decreased vision in the right eye 21 days after a fourth IVBr injection. Examination revealed scleritis with high intraocular pressure but no anterior chamber or fundus inflammation. STTA and topical eye drops were performed. One month later, scleritis improved but visual acuity didn't due to progression of nAMD. Intraocular inflammation following IVBr injection may progress to the posterior segment. Scleritis can occur after IVBr injection, and topical eye drops alone may not be sufficient for initial treatment. Clinicians should consider the possibility of scleritis in patients with worsening inflammation after IVBr injection.
Sections du résumé
BACKGROUND
BACKGROUND
This study reports the first cases of scleritis following intravitreal brolucizumab (IVBr) injection for nAMD, emphasizing the need to be aware of the possibility of scleritis following IVBr injections.
CASE PRESENTATION
METHODS
Case 1. A 74-year-old Japanese man with nAMD complained of conjunctivitis and decreased vision in the right eye 8 days after his eighth IVBr injection. Examination revealed scleritis without anterior inflammation. Topical 0.1% betamethasone and 0.3% gatifloxacin eye drops were started. The scleritis worsened in the following 2 weeks and became painful. He underwent sub-Tenon's capsule triamcinolone acetonide (STTA) injection. Two days later, he returned with a complaint of severe vision loss. Fundus examination revealed retinal artery occlusion, vasculitis, and vitreous opacity in the right eye. Vitreous surgery was performed.
CASE 2
METHODS
An 85-year-old Japanese woman with nAMD in the right eye complained of reddening of the eye 27 days after her fifth IVBr injection. Examination showed conjunctivitis and scleritis without anterior inflammation in the right eye. She was started on 0.1% fluorometholone and 0.5% levofloxacin hydrate eye drops. The scleritis worsened in the following 3 weeks. Her treatment was switched to 0.1% betamethasone eye drops. One month later, the scleritis had improved and a sixth IVBr injection was administered. There was no worsening of the scleritis at that time. However, 1 month after a seventh IVBr injection, she complained of severe hyperemia and decreased vision. Fundus examination revealed vitreous opacification. She underwent STTA, and the vitreous opacity improved in 24 days. Case 3. A 57-year-old Japanese man with nAMD complained of pain and decreased vision in the right eye 21 days after a fourth IVBr injection. Examination revealed scleritis with high intraocular pressure but no anterior chamber or fundus inflammation. STTA and topical eye drops were performed. One month later, scleritis improved but visual acuity didn't due to progression of nAMD.
CONCLUSIONS
CONCLUSIONS
Intraocular inflammation following IVBr injection may progress to the posterior segment. Scleritis can occur after IVBr injection, and topical eye drops alone may not be sufficient for initial treatment. Clinicians should consider the possibility of scleritis in patients with worsening inflammation after IVBr injection.
Identifiants
pubmed: 38419100
doi: 10.1186/s13256-024-04402-9
pii: 10.1186/s13256-024-04402-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Informations de copyright
© 2024. The Author(s).
Références
Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y, Kubota T. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85(10):1153–7.
doi: 10.1136/bjo.85.10.1153
pubmed: 11567955
pmcid: 1723746
Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5(5): CD012208.
pubmed: 32374423
Patil NS, Dhoot AS, Popovic MM, Kertes PJ, Muni RH. Risk of intraocular inflammation after injection of antivascular endothelial growth factor agents: a meta-analysis. Retina. 2022;42(11):2134–42.
doi: 10.1097/IAE.0000000000003582
pubmed: 36269802
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050–9.
doi: 10.1016/j.ophtha.2020.11.011
pubmed: 33207259
Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11(1):6759.
doi: 10.1038/s41598-021-86014-7
pubmed: 33762600
pmcid: 7990919
Nguyen HV, Tan GS, Tapp RJ, Mital S, Ting DS, Wong HT, et al. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore. Ophthalmology. 2016;123(12):2571–80.
doi: 10.1016/j.ophtha.2016.08.021
pubmed: 27726962
Montesel A, Bucolo C, Sallo FB, Eandi CM. Short-term efficacy and safety outcomes of brolucizumab in the real-life clinical practice. Front Pharmacol. 2021;12: 720345.
doi: 10.3389/fphar.2021.720345
pubmed: 34803674
pmcid: 8600267
Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021;259(9):2857–9.
doi: 10.1007/s00417-021-05136-w
pubmed: 33723637
pmcid: 8380561
Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–59.
doi: 10.1016/j.ophtha.2020.04.017
pubmed: 32344075
Baumal CR, Bodaghi B, Singer M, Tanzer DJ, Seres A, Joshi MR, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519–27.
doi: 10.1016/j.oret.2020.09.020
pubmed: 33007521
Abdel-Aty A, Gupta A, Del Priore L, Kombo N. Management of noninfectious scleritis. Ther Adv Ophthalmol. 2022;14:25158414211070880.
pubmed: 35083421
pmcid: 8785299
Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111(3):501–6.
doi: 10.1016/j.ophtha.2003.06.006
pubmed: 15019326
Kimura N, Takahashi H, Sakamoto S, Yanagi Y, Maeshima N, Minamimoto A, et al. Microvolume analysis of aflibercept in aqueous humor using mass spectrometry. Transl Vis Sci Technol. 2022;11(6):7.
doi: 10.1167/tvst.11.6.7
pubmed: 35671043
pmcid: 9187940
Armbrust KR, Kopplin LJ. Characteristics and outcomes of patients with scleritis in the IRIS® Registry (Intelligent Research in Sight) Database. Ophthalmol Sci. 2022;2(3): 100178.
doi: 10.1016/j.xops.2022.100178
pubmed: 36245751
pmcid: 9559886
Heinz C, Bograd N, Koch J, Heiligenhaus A. Ocular hypertension and glaucoma incidence in patients with scleritis. Graefes Arch Clin Exp Ophthalmol. 2013;251(1):139–42.
doi: 10.1007/s00417-012-2108-3
pubmed: 22820814